Integrin αvβ3 as a target for blocking HIV-1 tat-induced endothelial cell activation in vitro and angiogenesis in vivo

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 25, Issue 11, 2005, Pages 2315-2320

  Urbinati, Chiara ^a   Mitola, Stefania ^a   Tanghetti, Elena ^a   Kumar, Chandra ^b   Waltenberger, Johannes ^c   Ribatti, Domenico ^d   Presta, Marco ^a   Rusnati, Marco ^a,e  

^a UNIVERSITY OF BRESCIA   (Italy)

^b MERCK RESEARCH LABORATORIES   (United States)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF BARI   (Italy)

^e Department of Biomedical Sciences and Biotechnology ^*  (Italy)

Author keywords

Angiogenesis; Endothelium; HIV 1; Integrin; Tat

Indexed keywords

ARGINYLGLYCYLASPARTIC ACID; ARGINYLGLYCYLASPARTIC ACID BASED PEPTIDOMIMETIC AGENT; FOCAL ADHESION KINASE; HEPARAN SULFATE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PHOSPHOTRANSFERASE; PROTEOGLYCAN; SCH 221153; SYNTHETIC PEPTIDE; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2; VITRONECTIN RECEPTOR; ARGINYL-GLYCYL-ASPARTIC ACID; BENZIMIDAZOLE DERIVATIVE; OLIGOPEPTIDE; PEPTIDE FRAGMENT; TAT (17 25); TAT (17-25);

ANGIOGENESIS; ANIMAL CELL; ARTICLE; ATHEROSCLEROSIS; BINDING ASSAY; CELL ACTIVATION; CELL ADHESION; CELL MEMBRANE; CELL MOTILITY; CELL PROLIFERATION; CHICK EMBRYO; CHORIOALLANTOIS; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; ENDOTHELIUM CELL; ENZYME ACTIVATION; FETUS; HELA CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; UMBILICAL VEIN; ANIMAL; AORTA; CATTLE; CELL LINE; CHICKEN; CYTOLOGY; DRUG ANTAGONISM; IN VITRO STUDY; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION; SWINE; VASCULAR ENDOTHELIUM; VIROLOGY;

ANIMALS; AORTA; BENZIMIDAZOLES; CATTLE; CELL LINE, TRANSFORMED; CHICK EMBRYO; CHICKENS; ENDOTHELIUM, VASCULAR; GENE PRODUCTS, TAT; HIV INFECTIONS; HIV-1; HUMANS; INTEGRIN ALPHAVBETA3; NEOVASCULARIZATION, PATHOLOGIC; OLIGOPEPTIDES; PEPTIDE FRAGMENTS; SIGNAL TRANSDUCTION; SWINE; UMBILICAL VEINS;

EID: 27644440286     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000186182.14908.7b     Document Type: Article

References (36)

1. Gatignol A, Jeang KT. Tat as a transcriptional activator and a potential therapeutic target for HIV-1. Adv Pharmacol. 2000;48:209-227.
2. Noonan D, Albini A. From the outside in: extracellular activities of HIV Tat. Adv Pharmacol. 2000;48:229-250.
3. Dewhurst S, Gelbard HA, Fine SM. Neuropathogenesis of AIDS. Mol Med Today. 1996;2:16-23.
4. Krishnaswamy G, Chi DS, Kelley JL, Sarubbi F, Smith JK, Peiris A. The cardiovascular and metabolic complications of HIV infection. Cardiol Rev. 2000;8:260-268.
5. Rusnati M, Presta M. HIV-1 Tat protein and endothelium: from protein/cell interaction to AIDS-associated pathologies. Angiogenesis. 2002; 5:141-151.
6. Matzen K, Dirkx AE, oude Egbrink MG, Speth C, Gotte M, Ascherl G, Grimm T, Griffioen AW, Sturzl M. HIV-1 Tat increases the adhesion of monocytes and T-cells to the endothelium in vitro and in vivo: implications for AIDS-associated vasculopathy. Virus Res. 2004;104:145-155.
7. Paladugu R, Fu W, Conklin BS, Lin PH, Lumsden AB, Yao Q, Chen C. HIV Tat protein causes endothelial dysfunction in porcine coronary arteries. J Vasc Surg. 2003;38:549-555; discussion 555-546.
8. Rusnati M, Presta M. HIV-1 Tat protein: a target for the development of anti-AIDS therapies. Drug Fut. 2002;27:481-493.
9. Chang HC, Samaniego F, Nair BC, Buonaguro L, Ensoli B. HIV-1 Tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix-associated heparan sulfate proteoglycans through its basic region. Aids. 1997;11:1421-1431.
10. 3 integrin-dependent activation of focal adhesion kinase mediates NF-κB activation and motogenic activity by HIV-1 Tat in endothelial cells. J Cell Sci. 2005;118:3949-3958.
11. Mitola S, Soldi R, Zanon I, Barra L, Gutierrez MI, Berkhout B, Giacca M, Bussolino F. Identification of specific molecular structures of human immunodeficiency virus type 1 Tat relevant for its biological effects on vascular endothelial cells. J Virol. 2000;74:344-353.
12. Brake DA, Debouck C, Biesecker G. Identification of an Arg-Gly-Asp (RGD) cell adhesion site in human immunodeficiency virus type 1 transactivation protein, tat. J Cell Biol. 1990;111:1275-1281.
13. Kumar CC, Malkowski M, Yin Z, Tanghetti E, Yaremko B, Nechuta T, Varner J, Liu M, Smith EM, Neustadt B, Presta M, Armstrong L. Inhibition of angiogenesis and tumor growth by SCH221153, a dual alpha(v)beta3 and alpha(v)beta5 integrin receptor antagonist. Cancer Res. 2001;61:2232-2238.
14. Rusnati M, Tanghetti E, Dell'Era P, Gualandris A, Presta M. alphavbeta3 integrin mediates the cell-adhesive capacity and biological activity of basic fibroblast growth factor (FGF-2) in cultured endothelial cells. Mol Biol Cell. 1997;8:2449-2461.
15. Rusnati M, Tulipano G, Urbinati C, Tanghetti E, Giuliani R, Giacca M, Ciomei M, Corallini A, Presta M. The basic domain in HIV-1 Tat protein as a target for polysulfonated heparin-mimicking extracellular Tat antagonists. J Biol Chem. 1998;273:16027-16037.
16. Urbinati C, Bugatti A, Oreste P, Zoppetti G, Waltenberger J, Mitola S, Ribatti D, Presta M, Rusnati M. Chemically sulfated Escherichia coli K5 polysaccharide derivatives as extracellular HIV-1 Tat protein antagonists. FEBS letters. 2004;568:171-177.
17. Rusnati M, Tulipano G, Spillmann D, Tanghetti E, Oreste P, Zoppetti G, Giacca M, Presta M. Multiple interactions of HIV-I Tat protein with size-defined heparin oligosaccharides. J Biol Chem. 1999;274: 28198-28205.
18. Albini A, Soldi R, Giunciuglio D, Giraudo E, Benelli R, Primo L, Noonan D, Salio M, Camussi G, Rockl W, Bussolino F. The angiogenesis induced by HIV-1 tat protein is mediated by the Flk-1/KDR receptor on vascular endothelial cells. Nat Med. 1996;2:1371-1375.
19. Tyagi M, Rusnati M, Presta M, Giacca M. Internalization of HIV-1 tat requires cell surface heparan sulfate proteoglycans. J Biol Chem. 2001; 276:3254-3261.
20. Ruegg C, Mariotti A. Vascular integrins: pleiotropic adhesion and signaling molecules in vascular homeostasis and angiogenesis. Cell Mol Life Sci. 2003;60:1135-1157.
21. Milani D, Mazzoni M, Zauli G, Mischiati C, Gibellini D, Giacca M, Capitani S. HIV-1 Tat induces tyrosine phosphorylation of p125FAK and its association with phosphoinositide 3-kinase in PC12 cells. Aids. 1998; 12:1275-1284.
22. Demarchi F, d'Adda di Fagagna F, Falaschi A, Giacca M. Activation of transcription factor NF-kappaB by the Tat protein of human immunodeficiency virus type 1. J Virol. 1996;70:4427-4437.
23. Folkman J, Klagsbrun M. Angiogenic factors. Science. 1987;235: 442-447.
24. Nagashima K, Endo A, Ogita H, Kawana A, Yamagishi A, Kitabatake A, Matsuda M, Mochizuki N. Adaptor protein Crk is required for ephrin-B1-induced membrane ruffling and focal complex assembly of human aortic endothelial cells. Mol Biol Cell. 2002;13:4231-4242.
25. Ridley AJ, Paterson HF, Johnston CL, Diekmann D, Hall A. The small GTP-binding protein rac regulates growth factor-induced membrane ruffling. Cell. 1992;70:401-410.
26. Caputo A, Boarini BM, Mantovani I, Corallini A, Barbanti-Brodano G. Multiple functions of human immunodeficiency virus type 1 Tat protein in the pathogenesis of AIDS. Recent Researches Developmental Virology. 1999;1:753-778.
27. Conforti G, Dominguez-Jimenez C, Zanetti A, Gimbrone MA Jr, Cremona O, Marchisio PC, Dejana E. Human endothelial cells express integrin receptors on the luminal aspect of their membrane. Blood. 1992; 80:437-446.
28. Tanghetti E, Ria R, Dell'Era P, Urbinati C, Rusnati M, Ennas MG, Presta M. Biological activity of substrate-bound basic fibroblast growth factor (FGF2): recruitment of FGF receptor-1 in endothelial cell adhesion contacts. Oncogene. 2002;21:3889-3897.
29. Barillari G, Sgadari C, Palladino C, Gendelman R, Caputo A, Morris CB, Nair BC, Markham P, Nel A, Sturzl M, Ensoli B. Inflammatory cytokines synergize with the HIV-1 Tat protein to promote angiogenesis and Kaposi's sarcoma via induction of basic fibroblast growth factor and the alpha v beta 3 integrin. J Immunol. 1999;163:1929-1935.
30. Morini M, Benelli R, Giunciuglio D, Carlone S, Arena G, Noonan DM, Albini A. Kaposi's sarcoma cells of different etiologic origins respond to HIV-Tat through the Flk-1/KDR (VEGFR-2): relevance in AIDS-KS pathology. Biochem Biophys Res Commun. 2000;273:267-271.
31. Rader C, Popkov M, Neves JA, Barbas CF, 3rd. Integrin alpha(v)beta3 targeted therapy for Kaposi's sarcoma with an in vitro evolved antibody. Faseb J. 2002;16:2000-2002.
32. Arasteh K, Hannah A. The role of vascular endothelial growth factor (VEGF) in AIDS-related Kaposi's sarcoma. Oncologist. 2000;5 (Suppl I);I28-I31.
33. Ensoli B, Gendelman R, Markham P, Fiorelli V, Colombini S, Raffeld M, Cafaro A, Chang HK, Brady JN, Gallo RC. Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi's sarcoma. Nature. 1994;371:674-680.
34. Barillari G, Gendelman R, Gallo RC, Ensoli B. The Tat protein of human immunodeficiency virus type 1, a growth factor for AIDS Kaposi sarcoma and cytokine-activated vascular cells, induces adhesion of the same cell types by using integrin receptors recognizing the RGD amino acid sequence. Proc Natl Acad Sci USA. 1993;90:7941-7945.
35. Wang W, Borchardt RT, Wang B. Orally active peptidomimetic RGD analogs that are glycoprotein IIb/IIIa antagonists. Curr Med Chem. 2000; 7:437-453.
36. Ghandehari H, Sharan R, Rubas W, Killing WM. Molecular modeling of arginine-glycine-aspartic acid (RGD) analogs: relevance to transepithelial transport. J Pharm Pharm Sci. 2001;4:32-41.